We report the case of a female patient with double endocrine neoplasia type 1. Echoendoscopy (EUS) revealed two nodular hypoechoic lesions (Fig. 1), with a color Doppler hypervascular pattern located in the pancreas. We carried out an EUS-guided fine-needle aspiration (FNA) biopsy [1] (Fig. 2), which showed a neuroendocrine islet tumor in the pathology report 2 weeks later. Tumor sizes were 11 and 7 mm respectively.

Because the patient refused surgical therapy, we performed an ethanol injection under EUS guidance into the nodule. Ethanol concentration was 40% [2] and its amount did not exceed 2 ml. At the same time celiac plexus neurolysis was carried out to control abdominal pain. Clinical, biochemical, and transabdominal ultrasonography controls after the EUS-guided injection session showed a neuroendocrine islet tumor.

Two months later, we performed an Octreoscan and serum tests of vasoactive intestinal peptide (VIP) and chromogranin A (CgA), which were normal. EUS with contrast enhanced detected areas of fibrosis [3]. At present, after a follow-up period of 18 months, the patient is asymptomatic, without recurrent disease; abdominal nuclear magnetic resonance is negative.

EUS is particularly useful in the assessment of small pancreatic tumors missed by other imaging techniques [3-5]. EUS-FNA [1] is a gold standard in the management of pancreatic tumors. Unusually, we have explored a new field of EUS that permits injection of drugs directly into the tumor. In our experience, if surgical therapy is refused by the patient or contraindicated because of poor general health conditions, EUS-guided injection is a safe and effective treatment in endocrine lesions, which can eliminate hormonal alterations.

It has been demonstrated that ethanol injection is a safe technique for the treatment of hepatic and thyroid lesions [6]. In our case we have used the same technique to treat pancreatic lesions, thus avoiding surgery, which has high morbidity and mortality; the duration of hospitalization was also reduced. A multicenter study is necessary to establish a standardized procedure for EUS-ethanol injection in neuroendocrine pancreatic tumors.

EUS is particularly useful in the assessment of small pancreatic tumors missed by other imaging techniques [3-5]. EUS-FNA [1] is a gold standard in the management of pancreatic tumors. Unusually, we have explored a new field of EUS that permits injection of drugs directly into the tumor. In our experience, if surgical therapy is refused by the patient or contraindicated because of poor general health conditions, EUS-guided injection is a safe and effective treatment in endocrine lesions, which can eliminate hormonal alterations.

It has been demonstrated that ethanol injection is a safe technique for the treatment of hepatic and thyroid lesions [6]. In our case we have used the same technique to treat pancreatic lesions, thus avoiding surgery, which has high morbidity and mortality; the duration of hospitalization was also reduced. A multicenter study is necessary to establish a standardized procedure for EUS-ethanol injection in neuroendocrine pancreatic tumors.

Endoscopy_UCTN_Code_CPL_1AL_2AD
N. Muscatiello¹, A. Salcuni², L. Macarini³, M. Cignarelli², S. Prencipe¹, M. di Maso¹, M. Castriota⁴, V. D’Agnessa⁴, E. Ierardi¹

¹ Gastroenterology Unit, Ospedali Riuniti, Foggia, Italy
² Endocrinology Unit, Ospedali Riuniti, Foggia, Italy
³ Radiology Unit, Ospedali Riuniti, Foggia, Italy
⁴ Pathology Unit, Ospedali Riuniti, Foggia, Italy

References


Bibliography

Endoscopy 2007; 39: E258 – E259
© Georg Thieme Verlag KG Stuttgart - New York - ISSN 0013-726X

Corresponding author
N. Muscatiello, MD
Gastroenterology Unit
Ospedali Riuniti
Viale Luigi Pinto, 1
71100 Foggia
Italy
Fax: +39-881733870
nmuscatiello@libero.it